The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

The following is a summary of “Nomogram for predicting proliferative lupus nephritis in patients with low-level proteinuria,” ...

The following is a summary of “Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year ...

in proliferative lupus nephritis (LN) patients who discontinued immunosuppressive therapy (IST), as well as the long-term renal outcomes following RR. Methods Retrospective, single-centre study of ...

These datasets include high-resolution images of brain cancer and kidney disease (Lupus Nephritis), forming the ... aiming to digitise tissue biopsy slides. Supported by the Technological ...

The effort, dubbed India Pathology Dataset (IPD) project, a collaborative initiative involving academia, hospitals, industry, and govt, aims to digitise tissue biopsy slides ... also compiled a ...

Additionally, B cells in the peripheral blood, kidney, skin, and bone marrow of lupus patients exhibit tissue-specific characteristics. For instance, pathogenic B cells in kidney tissue show high ...

Tacrolimus appears to have “synergistic” interactions with mycophenolate mofetil and cyclophosphamide for the treatment of renal involvement in systemic lupus erythematosus, according to ...